


Merck invites you to attend:

A Paradigm Shift: The Emerging Role of Adjuvant Immunotherapy in the Management of Patients with Renal cell Carcinoma

A Multidisciplinary Review

CONTENT EXPERTS:

Dr. Ricardo Rendon
Uro-Oncologist
Halifax, NS



Dr. Ricardo Rendon did his medical school and residency in Bogota, Colombia. He subsequently completed a clinical and research Uro-Oncology Fellowship at the University of Toronto, Canada and a Masters in Community Health Clinical Epidemiology. He joined Dalhousie University in Halifax, Canada in 2001 where he is a Professor in the Department of Urology and the Director of Research and Clinical Trials. He is the Chair of the Genito-Urinary Cancer Site Team, Nova Scotia Health Authority Cancer Program. Dr. Rendon is currently the Vice-President of Education of the Canadian Urological Association and Chair of the Canadian Urologic Oncology Group. While his clinical practice focuses on all areas of urologic oncology, his research focuses on renal cell carcinoma, advanced prostate cancer and urothelial cell carcinoma. He has authored over 184 peer-reviewed manuscripts and has been particularly active in the development of clinical guidelines and national and international collaborations in kidney, bladder, upper tract urothelial cell carcinoma and prostate cancer.

Dr. Sohaib Al-Asaad
Medical Oncologist
St. John's, NF



Father. Husband. Medical Oncologist. Educator.

Sohaib Al-Asaad completed medical school at Dalhousie University and Internal Medicine at Memorial University. He subsequently completed subspecialty training in medical oncology and a fellowship in genitourinary malignancies at Western University, alongside a Masters in Health Professions Education from Maastricht University. He is an associate professor of oncology and tenured faculty member of Memorial University. His clinical practice focuses on all areas of genitourinary oncology, alongside Neuroendocrine tumors. He has presented on diverse subject matter locally, nationally and internationally. He has a passion for medical education and is the Associate Dean of Postgraduate Medical Education at Memorial University. He is extensively involved at the Royal College of Physicians and Surgeons of Canada, actively supporting accreditation, assessment as well as curricular matters on a national scale. He is the Atlantic region representative at the medical oncology specialty committee.

Merck invites you to attend:

A Paradigm Shift: The Emerging Role of Adjuvant Immunotherapy in the Management of Patients with Renal cell Carcinoma

A Multidisciplinary Review

PROGRAM RATIONALE

Based on current and emerging evidence, the rationale of this program is to have a Medical Oncologist and a Uro-Oncologist present on from their different perspectives. on the impact on clinical practice, the specific populations that benefit from this evidence and to better understand the specific referral patterns that require implementation.

LEARNING OBJECTIVES

1. Review evidence and guidelines for immunotherapy treatment options for the management of adjuvant RCC.
2. Discuss updates related to the adjuvant RCC treatment paradigm.
3. Review the roles of the Multidisciplinary Team in the clinical management of adjuvant RCC.
4. Discuss optimization of the RCC patient referral pathway.
5. Discuss best practices in optimization of patient care.

DATE & TIME

Friday, June 21st

12:00 PM – 1:00 PM AST

LOCATION

Westin Nova Scotian

1181 Hollis St.

Halifax, NS

